BEDMINSTER, N.J., Feb. 21, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, announced today its new Specialty Brands office site in Bedminster, N.J. earned recognition as a 2017 Somerset County Planning Board Land Development Award honoree in the Commercial category. Awards were presented Tuesday evening at the County Administration Building in Somerville.
Mallinckrodt officially opened its Specialty Brands office in October 2017 at 1405-1425 U.S. Route 206. The office is home to a workforce of nearly 500 that supports marketed and development products in the company's hospital and autoimmune and rare diseases businesses.
"We are pleased to be honored alongside a wide range of development projects in our community, recognized for high levels of design and creativity," said Mark Trudeau, Mallinckrodt President and Chief Executive Officer. "Bedminster has been an excellent setting for our company, and significant design and planning efforts have resulted in the build-out of a collaborative, dynamic work space for our New Jersey-based employees and a site that will meet the needs of our fast-transforming business."
Mallinckrodt's investment includes a complete renovation of 190,000 square feet of office space, with the company occupying more than 80 percent of the building, and design of an open, light-filled work environment providing multiple ways to work and collaborate. The office complex had been vacant for several years, and Mallinckrodt led renovation of the buildings into Class A office space with a full-service cafeteria, fitness center, and a data center. More than 70 percent of the space is open floor plan, and the site can accommodate future growth.
New energy-efficient LED lighting replaced older fluorescent interior lighting, as part of an energy efficient master lighting control system. Exterior improvements to the 23-acre site included the removal of 75 dead or damaged trees, planting of 115 new indigenous evergreen and shade trees, installation of new indigenous ground cover and mulched plant beds, and upgraded entry paving to meet all accessibility standards.
A program of the Somerset County Planning Board, the 35th Annual Land Development and Planning Awards Program sought nominations for projects that are exceptionally well-designed and planned. Selection criteria were:
- Imaginative planning using a creative, new approach to a planning issue or concern;
- Innovative site design demonstrating a unique approach to physical design representing high standards of site planning and engineering;
- Demonstrated cooperation between local officials and applicants promoting sound planning practices and public objectives;
- Adaptive-use projects that retain the original quality or characteristic form of the building; and
- Projects that showcase innovative, cost-effective energy conservation and high-efficiency solutions and/or renewable energy technologies that enhance community sustainability, improve resiliency, advance sustainability goals, and initiatives, save energy and reduce greenhouse gas emissions.
To learn more about Mallinckrodt or to explore career opportunities with the company, visit www.mallinckrodt.com.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Senior Communications Manager
Chief Public Affairs Officer
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations
Mallinckrodt, the "M" brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 2/2018
SOURCE Mallinckrodt Pharmaceuticals